

Research article

Open Access

Analysis of the transcriptional activity of endogenous NFAT5 in primary cells using transgenic NFAT-luciferase reporter mice

Beatriz Morancho¹, Jordi Minguillón¹, Jeffery D Molkenin², Cristina López-Rodríguez¹ and Jose Aramburu*¹

Address: ¹Immunology Unit, Department of Experimental and Health Sciences, Universitat Pompeu Fabra, and Barcelona Biomedical Research Park-PRBB, Carrer Dr Aiguader 88, 08003 Barcelona, Spain and ²Division of Molecular Cardiovascular Biology, Department of Pediatrics, Children's Hospital Medical Center, 3333 Burnet Ave, Cincinnati, OH 45229-3039, USA

Email: Beatriz Morancho - beatriz.morancho@upf.edu; Jordi Minguillón - jordi.minguillon@upf.edu; Jeffery D Molkenin - jeff.molkenin@cchmc.org; Cristina López-Rodríguez - cristina.lopez-rodriguez@upf.edu; Jose Aramburu* - jose.aramburu@upf.edu

* Corresponding author

Published: 25 January 2008

Received: 5 September 2007

BMC Molecular Biology 2008, 9:13 doi:10.1186/1471-2199-9-13

Accepted: 25 January 2008

This article is available from: <http://www.biomedcentral.com/1471-2199/9/13>

© 2008 Morancho et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background: The transcription factor NFAT5/TonEBP regulates the response of mammalian cells to hypertonicity. However, little is known about the physiopathologic tonicity thresholds that trigger its transcriptional activity in primary cells. Wilkins et al. recently developed a transgenic mouse carrying a luciferase reporter (9xNFAT-Luc) driven by a cluster of NFAT sites, that was activated by calcineurin-dependent NFATc proteins. Since the NFAT site of this reporter was very similar to an optimal NFAT5 site, we tested whether this reporter could detect the activation of NFAT5 in transgenic cells.

Results: The 9xNFAT-Luc reporter was activated by hypertonicity in an NFAT5-dependent manner in different types of non-transformed transgenic cells: lymphocytes, macrophages and fibroblasts. Activation of this reporter by the phorbol ester PMA plus ionomycin was independent of NFAT5 and mediated by NFATc proteins. Transcriptional activation of NFAT5 in T lymphocytes was detected at hypertonic conditions of 360–380 mOsm/kg (isotonic conditions being 300 mOsm/kg) and strongly induced at 400 mOsm/kg. Such levels have been recorded in plasma in patients with osmoregulatory disorders and in mice deficient in aquaporins and vasopressin receptor. The hypertonicity threshold required to activate NFAT5 was higher in bone marrow-derived macrophages (430 mOsm/kg) and embryonic fibroblasts (480 mOsm/kg). Activation of the 9xNFAT-Luc reporter by hypertonicity in lymphocytes was insensitive to the ERK inhibitor PD98059, partially inhibited by the PI3-kinase inhibitor wortmannin (0.5 μM) and the PKA inhibitor H89, and substantially downregulated by p38 inhibitors (SB203580 and SB202190) and by inhibition of PI3-kinase-related kinases with 25 μM LY294002. Sensitivity of the reporter to FK506 varied among cell types and was greater in primary T cells than in fibroblasts and macrophages.

Conclusion: Our results indicate that NFAT5 is a sensitive responder to pathologic increases in extracellular tonicity in T lymphocytes. Activation of NFAT5 by hypertonicity in lymphocytes was mediated by a combination of signaling pathways that differed from those required in other cell types. We propose that the 9xNFAT-Luc transgenic mouse model might be useful to study the physiopathological regulation of both NFAT5 and NFATc factors in primary cells.

Background

NFAT5/TonEBP belongs to the Rel family of transcription factors, which also comprises NF- κ B and the calcineurin-dependent NFATc proteins (NFAT1/NFATc2, NFAT2/NFATc1, NFAT3/NFATc4, NFAT4/NFATc3) [1,2]. Rel proteins have in common a conserved DNA binding domain, but do not display recognizable similarities outside of it. The DNA binding domain of NFAT5 is considered a hybrid between that of NF- κ B and NFATc proteins, since it is a constitutive dimer, structurally similar to NF- κ B, but has NFATc-like DNA sequence specificity, with its optimal binding site being a 5'-TGGAAA(C/A/T)A(T/A)-3' motif, in which the NFATc cognate element is 5'-(T/A/C)GGAA(A/G)-3' [2-4]. NFATc and NFAT5 differ substantially in their mechanisms of activation and biological function. NFATc proteins are characteristically activated by the phosphatase calcineurin in response to increases in intracellular calcium concentration [5,6], whereas NFAT5 is activated by hypertonicity [1]. Activation of NFAT5 is regulated by different kinases, such as the stress-activated kinase p38, Fyn [7], PKA [8], ERK [9], the PI3-kinase-related kinase (PIKK) ATM [10,11], and phosphoinositide 3-kinase (PI3-kinase) [11]. p38 has been shown to regulate NFAT5 in some cell types but not in others [7,12]. NFATc proteins play fundamental roles in the immune, nervous and cardiovascular systems (reviewed in [13-15]). NFAT5 allows mammalian cells to adapt to hypertonicity [16,17], by inducing the expression of osmoprotective proteins, such as aldose reductase (AR), Na⁺/Cl⁻-coupled betaine/ γ -aminobutyric acid transporter (BGT1), Na⁺-dependent myo-inositol transporter (SMIT), Na⁺ and Cl⁻-dependent taurine transporter (TauT), UT-A urea transporter, and Hsp70 (reviewed in [18] and [19]). NFAT5-deficient mice suffer severe atrophy of the renal medulla, a naturally hypertonic environment, and impaired lymphocyte function [16,17].

The osmoresponsive function of NFAT5 has been documented in diverse cell types, such as lymphocytes [3,20], embryonic fibroblasts [16,17], kidney cells [16,21], neurons [22,23], and cell lines of different lineages [10]. However, little is known about tonicity thresholds (physiologic or pathologic) at which NFAT5 is activated in specific types of primary cells. In this regard, a transgenic mouse model with an integrated NFAT5-responsive reporter would facilitate the analysis of its transcriptional regulation in primary cells and tissues. An NFAT-luciferase (9xNFAT-Luc) transgenic mouse carrying 9 copies of an NFAT site (5'-TGGAAAATT-3') positioned 5' to the minimal promoter of the α -myosin heavy chain gene was developed by Wilkins et al., who studied the role of the calcineurin-NFATc pathway in cardiac hypertrophy [24]. As described in the original article, luciferase activity was detectable in most organs and was highest in the brain, kidney and heart, indicating that the reporter was func-

tional in different types of tissues. Since the NFAT site used in the reporter construct almost coincided with an optimal binding site for NFAT5 (5'-TGGAAAAT-3'), we wondered whether it could be activated by this factor.

In this work we show that the 9xNFAT-Luc reporter is activated by NFAT5 in response to hypertonicity in transgenic primary T lymphocytes, macrophages and mouse embryo fibroblasts (MEF), and by NFATc proteins in response to calcineurin activation. Activation of NFAT5 in lymphocytes was detected in response to hypertonicity levels in the range measured in plasma in patients and animal models with osmoregulatory disorders. Activation of NFAT5 transcriptional activity by hypertonicity was substantially downregulated by the p38 inhibitors SB203580 and SB202190, and by inhibition of PIKK with 25 μ M LY294002. The reporter was partially sensitive to the calcineurin inhibitor FK506, the PI3-kinase inhibitor wortmannin (0.5 μ M), and the protein kinase A inhibitor H89, but was not inhibited by the ERK inhibitor PD98059. These results, together with others in the literature, suggest that activation of NFAT5 by hypertonicity involves different combinations of signaling pathways in different cell types. Our results indicate that 9xNFAT-Luc mice might constitute a useful tool to study the regulation of both NFAT5 and NFATc proteins and the effect of pharmacological modulators in different types of primary cells.

Results

Activation of the 9xNFAT-Luc reporter by NFAT5 or NFATc proteins in a stimulus-specific manner

We observed that the 9xNFAT-Luc reporter was comparably activated by hypertonicity or PMA plus ionomycin (P+I) in the human T lymphocyte cell line Jurkat (Figure 1A). Activation by P+I was suppressed by the calcineurin inhibitor FK506, whereas induction by hypertonicity was not. Hypertonicity-induced activation was downregulated by > 60% in cells transfected with the isolated dimerization domain of NFAT5 (DD5), which inhibits NFAT5 but not NFATc proteins [3], whereas activation by P+I was not significantly inhibited (Figure 1B). The VIVIT peptide, which disrupts the binding of calcineurin to NFATc proteins [25], prevented the activation of the reporter by P+I without affecting its induction by hypertonicity (Figure 1B). The 9xNFAT-Luc reporter was activated by hypertonicity levels between 380 to 530 mOsm/kg, comparably to a widely used NFAT5-dependent reporter driven by the enhancer of the aldose reductase gene [3,26] (Figure 1C). These results indicated that the 9xNFAT-Luc reporter could be activated by distinct types of stimuli: hypertonicity via NFAT5, and PMA plus ionomycin via the calcineurin-dependent NFATc proteins.

In order to conclusively confirm that the 9xNFAT-Luc reporter was activated by NFAT5 under hypertonic condi-





Figure 1

Activation of the 9xNFAT-luc reporter by NFATc or NFAT5. A) Jurkat T cells transfected with the 9xNFAT-Luc reporter were stimulated with PMA plus ionomycin (P+I) or cultured in hypertonic medium (500 mOsm/kg) without or with FK506 during 24 hours. Luciferase activity is represented as relative light units per second (RLU) after normalization with Renilla and endogenous lactate dehydrogenase. Mean \pm S.D of four independent experiments is shown. **B)** 9xNFAT-Luc and vectors encoding GFP, the NFAT5-inhibitory dimerization domain (DD5-GFP) or the NFATc-inhibitory peptide VIVIT (VIVIT-GFP) were transfected in Jurkat T cells. Cells were treated during 24 hours with PMA plus ionomycin or hypertonicity (500 mOsm/kg) in the absence or presence of FK506. Mean \pm S.D of three independent experiments is shown. N.S.: non statistically significant. **C)** Jurkat T cells transfected with the 9xNFAT-Luc reporter or the ORE-luc reporter were exposed to increasingly hypertonic media in the presence of FK506, or stimulated with PMA plus ionomycin without FK506. Mean \pm S.D of three independent experiments is shown.

tions, we bred NFAT5^{+/-} mice [16] into the 9xNFAT-Luc transgenic background to obtain 9xNFAT-Luc^{+/}/NFAT5^{-/-} mice. We derived mouse embryo fibroblasts (MEF), and also analyzed mature T cells and bone marrow-derived macrophages from several independent NFAT5^{-/-} adult mice. As shown in Figure 2A, hypertonicity activated the 9xNFAT-Luc reporter in NFAT5^{+/+} MEF, but not in NFAT5^{-/-} cells. Both cell types showed a comparable response to P+I, which was suppressed by FK506. Activation of the reporter by hypertonicity in NFAT5^{+/+} MEF was partially inhibited (30%) by FK506. Transfection of an NFAT5

expression vector in NFAT5^{-/-} MEF reconstituted their responsiveness to hypertonicity (Figure 2B). Results obtained with 9xNFAT-Luc transgenic T cells derived from NFAT5^{+/+} and NFAT5^{-/-} mice confirmed that activation of the reporter by hypertonicity was severely impaired in NFAT5^{-/-} cells, whereas activation by P+I was independent of NFAT5 (Table 1). Hypertonicity-induced activation of the 9xNFAT-Luc reporter was variably inhibited by FK506 in T lymphocytes. We also noticed that hypertonicity induced a weak activation of the reporter in NFAT5^{-/-} cells, which was also partially inhibited by FK506. It has been

**Figure 2**

Unresponsiveness of the 9xNFAT-Luc reporter to hypertonicity in NFAT5-deficient cells. A) NFAT5^{+/+} and NFAT5^{-/-} MEF were transfected with the 9xNFAT-Luc reporter and stimulated with PMA plus ionomycin or hypertonicity (460 mOsm/kg), with or without FK506, during 24 hours. Mean \pm S.D of three independent experiments is shown. **B)** NFAT5^{-/-} MEF were transfected with the 9xNFAT-Luc reporter and an empty vector (pBSK(+)) or an NFAT5 expression vector. Cells were stimulated with PMA plus ionomycin or hypertonicity (460 mOsm/kg), with or without FK506, during 24 hours. Mean \pm S.E.M of three independent experiments is shown.

recently shown that NFATc1 can be activated by hypertonicity [27], and thus it is possible that the residual activity induced by hypertonic stimulation in NFAT5^{-/-} T cells could be due to NFATc proteins. Nonetheless, our overall results in primary T lymphocytes, macrophages (see below), MEF and Jurkat T cells showed that activation of the 9xNFAT-Luc reporter by hypertonicity was predominantly attributable to NFAT5, while other factors made a much lesser contribution to this stimulus. On the other hand, we did not observe significant contribution of NFAT5 to the activation of the 9xNFAT-Luc reporter by P+I.

Hypertonicity threshold for NFAT5 activation

Studies on hypertonic stress responses in different types of mammalian cells usually utilize hypertonicity levels of 500 mOsm/kg or higher, although it is poorly understood where cells might be exposed to such elevated hypertonicity levels besides the renal medulla. Physiologic osmolality values in plasma, brain and lung in mice are close to 300 mOsm/kg, and between 330–340 mOsm/kg in thymus, spleen and liver [17]. In humans, normal plasma osmolality is \sim 290 mOsm/kg, but can rise to the range of 380 to 430 mOsm/kg in cases of severe hypernatremia [28], salt poisoning in infants [29], adipsic disorders with impairment of thirst perception [30–32], and renal pathologies [33,34]. Constitutively elevated plasma tonicity (\sim 400 mOsm/kg) has been reported in mice deficient in V2 vasopressin receptor [35], and in mice with congenital progressive hydronephrosis caused by a mutation in

aquaporin-2 [36]. In aquaporin-1-deficient mice, plasma tonicity can reach 517 mOsm/kg after 36 hours of water deprivation, despite which these can survive if water is administered to them again [37]. Elevation of the tonicity in plasma would expose different tissues to hypertonic stress and might activate NFAT5, as shown in rats where an acute rise of plasma osmolality to 420 mOsm/kg triggered a rapid increase in expression and nuclear accumulation of NFAT5 in neurons [22].

Titration of the responsiveness of the 9xNFAT-Luc reporter to hypertonicity in the T cell line Jurkat showed that the reporter was significantly activated by hypertonicity levels of \geq 380 mOsm/kg (Figure 1C). Proliferating T cells derived from splenocytes stimulated during 3 days with the mitogen concanavalin A (ConA) plus IL2 showed calcineurin-independent activation of the reporter at 430 mOsm/kg (Figure 3A). In the same type of cells, induction of NFAT5 expression was detected at lower tonicity values (330 mOsm/kg) than the activation of the reporter. In these experiments, stimulation with hypertonicity was done in the presence of the calcineurin inhibitor FK506 to prevent any potential contribution of NFATc proteins. When we measured the activity of the reporter in freshly isolated thymocytes and splenocytes, we detected its activation only in response to P+I, but not with hypertonicity (Figures 3B and 3C). These results suggested that optimal NFAT5-mediated activation of the transgenic reporter in lymphocytes depended on their activation state. In agreement with this, we found that a 24-hour stimulation of T

Table 1: Impaired activation of endogenous 9xNFAT-Luc transgenic reporter by hypertonicity in NFAT5-deficient lymphocytes.

		9xNFAT-Luc reporter activity (RLU)					
		Experiment # 1		Experiment # 2		Experiment # 2	
		NFAT5 +/+	NFAT5 -/-	NFAT5 +/+	NFAT5 -/-	NFAT5 +/+	NFAT5 -/-
<i>8-hour stimulation</i>							
300 mOsm/kg (isotonic)	- FK506	19	25	45	19	16	16
	+ FK506	11	13	18	16	7	8
430 mOsm/kg (hypertonic)	- FK506	1026	117	825	191	387	27
	+ FK506	720	83	1316	13	579	24
480 mOsm/kg (hypertonic)	- FK506	12616	540	5677	42	10901	273
	+ FK506	19543	435	2894	51	7403	102
PMA+ ionomycin (isotonic)	- FK506	2445	10087	2080	2494	1726	6364
	+ FK506	24	19	34	31	37	158
<i>24-hour stimulation</i>							
300 mOsm/kg (isotonic)	- FK506	21	21	21	20	19	33
	+ FK506	10	15	14	15	12	10
430 mOsm/kg (hypertonic)	- FK506	1351	188	297	239	348	102
	+ FK506	550	122	254	129	388	73
480 mOsm/kg (hypertonic)	- FK506	6930	359	1742	224	7267	245
	+ FK506	1507	232	1111	129	3977	129
PMA+ ionomycin (isotonic)	- FK506	1100	2516	791	825	418	1775
	+ FK506	15	17	16	8	30	30

Luciferase activity was measured in proliferating transgenic 9xNFAT-Luc T cells derived from littermate NFAT5^{+/+} and NFAT5^{-/-} mice after stimulation with hypertonic medium or PMA plus ionomycin, in the absence or presence of 100 nM FK506. Luciferase activity is represented as relative light units per second (RLU) after normalization with endogenous lactate dehydrogenase.

cells with mitogens conferred them the ability to respond to hypertonicity levels of 380 mOsm/kg (Figure 3C). Next, we analyzed whether the responsiveness of the reporter varied at different time points after T cells had been stimulated with mitogens. As shown in Figure 4A and Table 2, the response to hypertonicity was strongest when cells had been stimulated with mitogens for one day. In these cells, activation of the 9xNFAT-Luc reporter was robustly induced at 380 and 400 mOsm/kg, and was even detectable at 360 mOsm/kg in some of the experiments. The intensity of the response became weaker in T cells that had been cultured during 48 hours or longer (Figure 4A and Table 2). We also found that lymphocytes showed a lower hypertonicity threshold for NFAT5 activation than bone marrow-derived macrophages and MEF. As shown in Figure 4B, NFAT5-dependent activation of the 9xNFAT-Luc reporter in macrophages was observed at 430 mOsm/kg. It was noticeable that hypertonicity-induced activation of this reporter was insensitive to FK506 in macrophages. Activation of the reporter in MEF required a higher hypertonicity threshold (480 mOsm/kg) (Figure 4C).

Sensitivity of NFAT5 transcriptional activity to pharmacological inhibitors

NFAT5 is fundamental in the adaptation of mammalian cells to osmotic stress, and the regulation of its transcriptional function by signaling pathways in primary, non-transformed cells, has not been fully elucidated. We analyzed the transcriptional response to hypertonicity in T cells treated with inhibitors of signaling pathways that had been reported to regulate NFAT5 in other cell types. As shown in Figure 5A, activation of the 9xNFAT-Luc reporter was downregulated by the p38 inhibitors SB203580 and SB202190 (both at 10 μ M), and by inhibition of PI3K with 25 μ M LY294002. The reporter was insensitive to the ERK inhibitor PD98059 (10 μ M), and partially inhibited by the calcineurin inhibitor FK506 (100 nM), the PI3-kinase inhibitors wortmannin (0.5 μ M) and LY294002 (1 μ M), and the protein kinase A inhibitor H89 (2 μ M). In the same type of experiment, 25 μ M LY294002 also caused a mild inhibition of NFAT5 expression (Figure 5A). The JNK inhibitor SP600125 (10 μ M) yielded inconsistent results, and we only observed a 30% inhibition of the reporter in one of three independent experiments (not shown).




Figure 3
Activation of the transgenic 9xNFAT-Luc reporter in fresh and mitogen-activated lymphocytes. A) Proliferating transgenic 9xNFAT-Luc T cells were exposed to increasingly hypertonic media in the presence of FK506, or stimulated with PMA plus ionomycin during 24 hours. Left panel: luciferase activity (RLU) shown is the mean ± S.E.M of five independent experiments. Right panel: NFAT5 and pyruvate kinase (protein loading control) were detected by Western blotting. One representative experiment is shown out of three performed independently. **B)** Luciferase activity in 9xNFAT-Luc transgenic thymocytes exposed to increasingly hypertonic media in the presence of FK506, or stimulated with PMA plus ionomycin during 24 hours. Mean ± S.E.M of three independent experiments is shown. **C)** Luciferase activity in 9xNFAT-Luc transgenic splenocytes stimulated during 24 hours with hypertonicity or PMA plus ionomycin, either immediately after their purification, or after a 24-hour preactivation with concanavalin A plus IL2. One representative experiment is shown out of three performed independently.

Experiments in MEF showed that activation of the 9xNFAT-Luc reporter was also prevented by SB203580 and LY294002 (Figure 5B). In these cells, SB203580 partially reduced the accumulation of NFAT5 in response to hypertonicity, while 25 μM LY294002 caused a substantial inhibition of NFAT5 expression. These results revealed that LY294002-sensitive kinases regulated both the transcriptional activation of NFAT5 and its expression in response to hypertonicity in different cell types.

Discussion

We show that the 9xNFAT-Luc reporter integrated in transgenic cells is activated by endogenous NFAT5 in response to hypertonicity and by NFATc proteins in response to calcineurin activation. A previous report had shown that a chimeric reporter with NFAT5 sites inserted into the minimal IL2 promoter could be activated by NFAT5 in response to hypertonicity as well as PMA plus ionomycin in Jurkat T cells [38], suggesting that this factor might reg-

Table 2: Hypertonicity threshold required to activate the endogenous 9xNFAT-Luc reporter in transgenic lymphocytes.

Preactivation with ConA + IL2	Stimulus	9xNFAT-Luc reporter activity (RLU)			
		Experiment # 1	Experiment # 2	Experiment # 3	Experiment # 4
24 hours	300 mOsm/kg (isotonic)	398	446	761	662
	340 mOsm/kg	295	673	1628	690
	360 mOsm/kg	1254	933	1648	944
	380 mOsm/kg	11468	1622	6060	2353
	400 mOsm/kg	38768	22808	11061	6494
	PMA + ionomycin (isotonic)	7039	20428	12081	6647
48 hours	300 mOsm/kg (isotonic)	257	351	329	210
	340 mOsm/kg	159	397	441	311
	360 mOsm/kg	205	327	567	226
	380 mOsm/kg	1118	1121	1204	1258
	400 mOsm/kg	7105	7997	1891	3291
	PMA + ionomycin (isotonic)	2079	19702	1803	3638
72 hours	300 mOsm/kg (isotonic)	155	356	113	146
	340 mOsm/kg	136	357	131	214
	360 mOsm/kg	128	342	196	99
	380 mOsm/kg	188	379	260	148
	400 mOsm/kg	288	467	458	288
	PMA + ionomycin (isotonic)	11359	22321	2389	1511

Transgenic 9xNFAT-Luc splenocytes were activated with concanavalin A plus IL2 during 24 to 72 hours in isotonic medium, and then exposed to hypertonicity, or stimulated with PMA plus ionomycin for 24 hours. Luciferase activity is represented as relative light units per second (RLU) after normalization with endogenous lactate dehydrogenase.

ulate certain promoters in response to non-hypertonic stimuli. Our results in primary mouse lymphocytes, macrophages, MEF and Jurkat cells show a remarkable selectivity in the activation of the 9xNFAT-Luc reporter by NFAT5 in response to hypertonicity, and by NFATc proteins in response to PMA plus ionomycin. These experiments indicate that the specific recruitment of either NFATc or NFAT5 to DNA sites to which both factors can bind may be determined by the type of stimulus. This finding is in line with work by the Goldfeld laboratory, who showed that some sites in the TNF α promoter and the LTR of HIV could recruit both NFAT5 and NFATc [39,40], and that occupancy of the site by either type of transcription factor depended on the stimulus. Hypertonicity-mediated activation of the 9xNFAT-Luc reporter was variably inhibited by FK506 in primary T cells and MEF, although not in macrophages and Jurkat cells, suggesting that calcineurin can modulate the hypertonic stress response in some cell types. This observation is consistent with a recent report showing that calcineurin was a positive regulator of both NFATc1 and NFAT5 in the activation of the aquaporin 2 promoter by hypertonicity in murine collecting duct cells [27]. Altogether, results from previous work [3,27,38], and ours here indicate that calcineurin might enhance the activation of NFAT5 by hypertonicity in some cell types, although it is not generally essential for its function, in contrast to the strict require-

ment of this phosphatase in the activation of NFATc proteins.

The variable dependence of NFAT5 transcriptional activity on calcineurin in different cell types would need to be considered when using the 9xNFAT-Luc mice to study the activation of NFAT5 and NFATc proteins *in vivo* or in primary cultures from different organs. The use of calcineurin inhibitors in cell culture experiments, and parallel analysis of NFAT5-deficient cells, as we have shown here, would ensure that the measured reporter activity is derived from NFAT5 rather from NFATc. *In vivo*, however, calcineurin inhibitors might complicate the interpretation of results due to side effects such as nephrotoxicity, which might affect sodium and water homeostasis in the organism [41] and indirectly perturb the regulation of NFAT5 and NFATc proteins. Crosses between 9xNFAT-Luc mice and tissue-specific conditional knockout for calcineurin or NFAT proteins might prove useful to study these factors *in vivo*.

Our experiments, together with independent results from the literature, revealed some heterogeneity in the sensitivity of NFAT5 transcriptional activity to pharmacological inhibitors. Hypertonicity-induced activation of NFAT5 in T lymphocytes was substantially downregulated by the PI3-kinase and PIKK inhibitors wortmannin and




Figure 4
Hypertonicity threshold required to activate the 9xNFAT-Luc reporter in different cell types. A) Luciferase activity in 9xNFAT-Luc transgenic splenocytes treated during 24 hours with hypertonicity or PMA plus ionomycin, after having been preactivated with concanavalin A plus IL2 during 24 hours, 48 hours or 72 hours. One representative experiment is shown out of three performed independently (see Table 2). **B)** Luciferase activity in 9xNFAT-Luc transgenic bone marrow-derived macrophages from NFAT5^{+/+} and NFAT5^{-/-} mice exposed to increasing hypertonicity levels during 24 hours. Mean ± S.D of two independent experiments is shown. **C)** Luciferase activity in 9xNFAT-Luc transgenic bone marrow-derived macrophages exposed to increasing hypertonicity levels during 24 hours, in the absence or presence of FK506 (100 nM). Mean ± S.D of three independent experiments is shown. **D)** Luciferase activity in 9xNFAT-Luc transgenic mouse embryo fibroblasts exposed to increasing hypertonicity levels during 24 hours. Mean ± S.D of three independent experiments is shown. N.S.: non statistically significant.

LY294002. This result agreed with previous reports using Jurkat T cells and HEK293 cells [10,11]. We also found that inhibition of PIKK impaired the upregulation of NFAT5 expression by hypertonicity in non-transformed lymphocytes and MEF. ATM and other PIKK regulate the nuclear translocation of NFAT5 [42], but their involvement in upregulating NFAT5 expression had not been pre-

viously documented. These observations indicate that PIKK regulate different layers of NFAT5 function.

With regard to other pathways, we found that activation of NFAT5 was inhibited by two independent p38 inhibitors, SB203580 and SB202190. Reports indicate that p38 might not be a universal regulator of NFAT5, since Kultz et al., showed that a dominant negative construct of




Figure 5
Sensitivity of NFAT5 transcriptional activity and expression to pharmacological inhibitors. A) Transgenic 9xNFAT-Luc splenocytes preactivated during 24 hours with concanavalin plus IL2 were treated with hypertonicity (400 mOsm/kg, 24 hours) in the absence or presence of FK506 (100 nM), SB203580 or SB202190 (both at 10 μM), PD98059 (10 μM), H89 (2 μM), wortmannin (0.5 μM), or LY294002 (LY). Luciferase activity in the upper panel (mean ± S.D. of three independent experiments) is shown as percentage of the activity in the absence of inhibitors (100%). Western blotting in the lower panel shows NFAT5 and pyruvate kinase expression. **B)** Transgenic MEF were stimulated for 8 or 24 hours with hypertonicity (460 mOsm/kg) in the absence or presence of SB203580 (10 μM) or LY294002 (LY). Luciferase activity is shown in the upper panel (mean ± S.E.M. of three independent experiments). NFAT5 and pyruvate kinase expression are shown in the lower panel.

MKK3 failed to inhibit the NFAT5-dependent reporter ORE-Luc in PAP-HT25 rabbit renal medullary cells [12], whereas Ko et al., showed that both a dominant negative p38 construct and SB203580 effectively inhibited the same reporter in NIH3T3 and MEF [7]. Tsai et al., found that a dominant negative p38 also inhibited the NFAT5-regulated TauT and Hsp70 promoters in nucleus pulposus cells [9]. The same report also showed that a dominant negative ERK construct and the ERK inhibitor PD98059

partially inhibited NFAT5, whereas we found that activation of NFAT5 in primary mouse T cells was insensitive to PD98059. H89 had been reported to partially inhibit NFAT5 transcriptional activity in the HepG2 hepatocellular carcinoma cell line [8], and we obtained similar results in T cells. The JNK inhibitor SP600125 did not impair the activation of the 9xNFAT-Luc reporter in T cells (not shown), in agreement with previous reports showing that neither SP600125 [9] nor inhibition of JNK with a domi-

nant negative SEK1 construct [12] inhibited NFAT5 in other cell types. We interpret our results with inhibitors cautiously, as some might inhibit more than one single kinase (see [43,44], and [45] for a recent update). Nonetheless, our profiling of the sensitivity of NFAT5 to pharmacological inhibitors in T cells, together with previous reports, supports the notion that activation of NFAT5 by hypertonicity involves distinct combinations of regulators in different cell types. Unravelling the identity of kinases and properties of NFAT5-regulatory pathways in specific cell types would help to understand the relevance of osmotic stress responses in mammals.

While it is clear that the osmoprotective function of NFAT5 is critical in the renal medulla, a physiologically hypertonic environment [16], many other cell types can also express and activate this factor when exposed to hypertonic stress. However, its activation threshold under physiological or pathological tonicity conditions in different cell types is largely unknown. Our experiments show that activated T lymphocytes are sensitive to moderate increases in extracellular tonicity, and could induce NFAT5 expression at relatively low levels of hypertonicity (330 mOsm/kg), and detectable transcriptional activity of this factor at 360–380 mOsm/kg, which increased sharply at 400 mOsm/kg. Tonicity levels in the 360–400 mOsm/kg range have been recorded in the plasma of patients with osmoregulatory disorders and in aquaporin and vasopressin receptor-deficient mice [28-37]. The hypertonicity level required to stimulate the 9xNFAT-Luc reporter in lymphocytes varied with their activation state. The reporter did not respond to hypertonicity in resting lymphocytes, showed a robust response to 380 and 400 mOsm/kg in T cells that had been exposed to mitogens for 24 hours, and became less responsive in cells cultured during 48 to 72 hours. T cell activation by mitogens or antigen receptor causes a dramatic increase in biogenesis, cell growth and gene expression during the first 24–48 hours, that precedes the entry of the lymphocyte in a series of cell division rounds [46,47]. That T cells display a greater sensitivity to hypertonicity and a stronger NFAT5 transcriptional response in the first stages of their activation is likely relevant to ensure their function under potentially harmful osmotic stress conditions. In this regard, exposure of fresh NFAT5-deficient T cells to 370 mOsm/kg during the first 3 days of antigen receptor-induced activation reduced their proliferation rate by more than 60%, whereas normal lymphocytes were not affected [17]. Altogether, these observations indicate that pathologic elevations of the extracellular tonicity rapidly activate the expression and transcriptional activation of NFAT5 in lymphocytes to ensure an appropriate osmoprotective response.

Activation of the reporter in macrophages and MEF required higher tonicity levels than in lymphocytes. It is intriguing that diverse cell types appear to require different hypertonicity levels to activate NFAT5-mediated transcriptional responses. While lymphocytes, as shown here and by Go et al. [17], and possibly neurons [22] and macrophages can respond to hypertonicity levels that may occur in certain pathologic conditions, other cells such as fibroblasts require a hypertonicity threshold that is unlikely to be found out of the renal medulla. Investigating the gene expression programs regulated by increasing levels of hypertonicity in different cell types might provide clues about the biological relevance of this response.

Conclusion

Our study indicates that the 9xNFAT-Luc reporter can be selectively activated by NFAT5 or NFATc proteins in a stimulus-specific manner. Transgenic 9xNFAT-Luc mice might be used to analyze not only NFATc proteins, but also the transcriptional activation of NFAT5 by hypertonicity and its regulation by signaling pathways in primary cells and tissues. It was known that NFAT5 is fundamental to sustain cell function and viability in the renal medulla, a naturally hypertonic environment. Here we show that the expression and transcriptional activation of NFAT5 in lymphocytes are remarkably sensitive to pathologic disturbances of the extracellular tonicity. Similar studies using this transgenic mouse model combined with other approaches should help to elucidate the role of NFAT5 in response to physiopathological tonicity changes in different types of mammalian cells.

Methods

Reagents

Phorbol 12-myristate 13-acetate (PMA), the calcium ionophore ionomycin, FK506, and the protein kinase inhibitors H89, LY294002, PD98059, SB202190, SB203580, SP600125 and wortmannin were purchased from Calbiochem (Darmstadt, Germany).

Cell culture

The human T cell line Jurkat (Clone E6-1, American Type Culture Collection, #TIB 152) was kindly provided by Jeremy Luban (Columbia University College of Physicians and Surgeons, New York, NY) and maintained in Dulbecco's modified Eagle's Medium (DMEM) supplemented with 10% heat-inactivated fetal bovine serum, 2 mM L-glutamine, 1 mM sodium pyruvate, and 50 μ M β -mercaptoethanol (Gibco, Pasley, UK). Mouse embryonic fibroblasts (MEF), bone marrow-derived macrophages (BMDM), and mouse T lymphocytes were cultured in the above medium plus 100 μ M non-essential amino acids and penicillin-streptomycin (Gibco).

Mouse embryonic fibroblasts, macrophages, and lymphocytes

9xNFAT-Luc mice (line 15.1) [24] in FVB background, and NFAT5^{+/-} mice [16] in 129Sv background were bred and maintained under specific pathogen-free conditions, and handled according to institutional guidelines (PRBB Animal Care and Use Committee). MEF were prepared from 13.5-day embryos using the NIH3T3 protocol to obtain spontaneously immortalized cells [16]. Bone marrow-derived macrophages (BMDM) were obtained by culturing femur and tibia marrow cell suspensions in L-929 cell-conditioned medium as previously described [48]. Mouse L-929 cells were kindly provided by Antonio Celada (Barcelona Institute for Biomedical Research, Barcelona, Spain). Briefly, bone marrow cells were cultured (37°C, humidified 5% CO₂ atmosphere) in plastic tissue culture dishes (150 mm) in 40 ml of DMEM containing 10% FBS and 30% L-929 cell-conditioned medium as a source of M-CSF. Penicillin/Streptomycin were added. After 7 days of culture, macrophages were obtained as a homogenous population of adherent cells (>95% CD11b⁺). No differences were observed in the expansion and differentiation of macrophages derived from NFAT5^{+/+} or NFAT5^{+/-} mice (not shown). Splenocytes and thymocytes were isolated from 8–12 weeks old mice. Proliferating T cells were obtained by activating splenocytes with 2.5 µg/ml concanavalin A (Sigma, Steinheim, Germany) plus 25 ng/ml of recombinant human IL2 (Proleukin, Chiron, Amsterdam, The Netherlands) for three days. T lymphocytes (>95% CD3⁺) were cultured at 1 × 10⁶ cells/ml in fresh medium supplemented with IL2 for an additional 24 hours. Cells growing in IL2-supplemented isotonic medium (300 mOsm/kg) were treated with 10 nM PMA plus 0.3 µM ionomycin, or hypertonicity, by adding NaCl. Osmolarity of the culture medium was measured in a Fiske One-Ten Osmometer (Fiske Associates, Norwood, MA, USA). Over an isotonic baseline of 300 mOsm/kg, addition of 30 mM NaCl raised the osmolality to 360 mOsm/kg, 40 mM NaCl to 380 mOsm/kg, 50 mM NaCl to 400 mOsm/kg, and 90 mM NaCl to 480 mOsm/kg.

DNA constructs

The luciferase reporters 9xNFAT-Luc [24] and ORE-luc have been described [3]. Expression vectors for NFAT5 (Myc-NFAT5-GFP) [2], NFAT5 dimerization domain (DD5-GFP) [3], and the NFATc inhibitory peptide VIVIT (VIVIT-GFP) [25] were described. pEGFP-N1 (Clontech, Palo Alto, CA, USA), pTK-Renilla (Promega, Madison, WI, USA), and pBlueScript SK+ (pBSK+) (Stratagene, La Jolla, CA, USA) are available commercially.

Transfections and reporter assays

Jurkat T cells were transfected by electroporation (Bio-Rad Gene Pulser, Bio-Rad, Hemel Hempstead, UK) [49], with luciferase reporter plasmids (0.3 µg/10⁶ cells) and TK-

Renilla (0.1 µg/10⁶ cells), together with either pEGFP-N1 (1 µg/10⁶ cells), VIVIT-GFP (2 µg/10⁶ cells), or DD5-GFP (2 µg/10⁶ cells). MEF were transfected by the calcium-phosphate method in 10-cm plates with luciferase reporter (1 µg/plate) plus TK-Renilla (1 µg/plate), and either pBSK+ (22 µg/plate) or NFAT5 expression vector (22 µg/plate). Transfected cells were stimulated in isotonic medium (300 mOsm/kg) with either 20 nM PMA plus 1 µM ionomycin or subjected to hypertonic conditions as indicated in figure legends. FK506 was used at 100 nM. Luciferase and Renilla were measured with the Dual-luciferase reporter system (Promega) with a Berthold FB12 luminometer (Berthold, Pforzheim, Germany). When reporters were transfected in cell lines, luciferase activity was normalized to Renilla and endogenous lactate dehydrogenase (LDH), which was proportional to the number of viable cells [49]. Luciferase activity in transgenic cells was normalized to endogenous LDH in the same lysate, measured with the CytoTox 96 Non-Radioactive Cytotoxicity Assay (Promega).

Western blot

Cell lysates, Western blotting, and enhanced chemiluminescent detection (Supersignal West Pico Chemiluminescent Substrate, Pierce, Rockford, IL, USA) were done as described [3]. PVDF membranes were probed with anti-NFAT5 (catalog number: PA1-023, Affinity Bioreagents; Golden CO, USA). Anti-Pyruvate kinase (AB1235; Chemicon, Hampshire, UK) was used as a protein loading control.

Authors' contributions

BM performed the experiments and participated in the design and writing of the manuscript. JM set up the culture of bone marrow-derived macrophages and did their phenotypical analysis. JDM provided the 9xNFAT-Luc transgenic mice and critically reviewed the manuscript. CLR provided NFAT5-deficient mice, isolated the MEF used in this study, and contributed to the design and drafting of the manuscript. JA designed the study, supervised the experiments and wrote the manuscript. All authors read and approved the final manuscript.

Acknowledgements

JA was supported by grants from the Ministry of Education and Science of Spain (BMC2002-00380, BFU2005-02247/BMC), Fundació la Marató TV3, and Distinció de la Generalitat de Catalunya per a la Promoció de la Recerca Universitària. CLR was supported by the Ramón y Cajal Researcher Programme and Ministry of Education and Science of Spain (BMC-2003-00882, SAF2006-04913), Marie Curie International Reintegration Programme, and Fundació la Marató TV3. BM is the recipient of an FI predoctoral fellowship from the Generalitat de Catalunya. JM was supported by a predoctoral FPI fellowship from the Ministry of Education and Science of Spain. We thank Verónica Santiago for excellent technical assistance.

References

- Miyakawa H, Woo SK, Dahl SC, Handler JS, Kwon HM: **Tonicity-responsive enhancer binding protein, a rel-like protein that stimulates transcription in response to hypertonicity.** *Proc Natl Acad Sci USA* 1999, **96**:2538-2542.
- Lopez-Rodriguez C, Aramburu J, Rakeman AS, Rao A: **NFAT5, a constitutively nuclear NFAT protein that does not cooperate with Fos and Jun.** *Proc Natl Acad Sci USA* 1999, **96**:7214-7219.
- Lopez-Rodriguez C, Aramburu J, Jin L, Rakeman AS, Michino M, Rao A: **Bridging the NFAT and NF-kappaB families: NFAT5 dimerization regulates cytokine gene transcription in response to osmotic stress.** *Immunity* 2001, **15**:47-58.
- Stroud JC, Lopez-Rodriguez C, Rao A, Chen L: **Structure of a TonEBP-DNA complex reveals DNA encircled by a transcription factor.** *Nat Struct Biol* 2002, **9**:90-94.
- Clipstone NA, Crabtree GR: **Identification of calcineurin as a key signalling enzyme in T-lymphocyte activation.** *Nature* 1992, **357**:695-697.
- Jain J, McCaffrey PG, Miner Z, Kerppola TK, Lambert JN, Verdine GL, Curran T, Rao A: **The T-cell transcription factor NFATp is a substrate for calcineurin and interacts with Fos and Jun.** *Nature* 1993, **365**:352-355.
- Ko BC, Lam AK, Kapus A, Fan L, Chung SK, Chung SS: **Fyn and p38 signaling are both required for maximal hypertonic activation of the osmotic response element-binding protein/tonicity-responsive enhancer-binding protein (OREBP/TonEBP).** *J Biol Chem* 2002, **277**:46085-46092.
- Ferraris JD, Persaud P, Williams CK, Chen Y, Burg MB: **cAMP-independent role of PKA in tonicity-induced transactivation of tonicity-responsive enhancer/osmotic response element-binding protein.** *Proc Natl Acad Sci USA* 2002, **99**:16800-16805.
- Tsai TT, Guttapalli A, Agrawal A, Albert TJ, Shapiro IM, Risbud MV: **MEK/ERK signaling controls osmoregulation of nucleus pulposus cells of the intervertebral disc by transactivation of TonEBP/OREBP.** *J Bone Miner Res* 2007, **22**:965-974.
- Irrarrazabal CE, Liu JC, Burg MB, Ferraris JD: **ATM, a DNA damage-inducible kinase, contributes to activation by high NaCl of the transcription factor TonEBP/OREBP.** *Proc Natl Acad Sci USA* 2004, **101**:8809-8814.
- Irrarrazabal CE, Burg MB, Ward SG, Ferraris JD: **Phosphatidylinositol 3-kinase mediates activation of ATM by high NaCl and by ionizing radiation: Role in osmoprotective transcriptional regulation.** *Proc Natl Acad Sci USA* 2006, **103**:8882-8887.
- Kultz D, Garcia-Perez A, Ferraris JD, Burg MB: **Distinct regulation of osmoprotective genes in yeast and mammals. Aldose reductase osmotic response element is induced independent of p38 and stress-activated protein kinase/Jun N-terminal kinase in rabbit kidney cells.** *J Biol Chem* 1997, **272**:13165-13170.
- Macian F: **NFAT proteins: key regulators of T-cell development and function.** *Nat Rev Immunol* 2005, **5**:472-484.
- Molkentin JD: **Calcineurin-NFAT signaling regulates the cardiac hypertrophic response in coordination with the MAPKs.** *Cardiovasc Res* 2004, **63**:467-475.
- Wu H, Peisley A, Graef IA, Crabtree GR: **NFAT signaling and the invention of vertebrates.** *Trends Cell Biol* 2007, **17**:251-260.
- Lopez-Rodriguez C, Antos CL, Shelton JM, Richardson JA, Lin F, Novobrantseva TI, Bronson RT, Igarashi P, Rao A, Olson EN: **Loss of NFAT5 results in renal atrophy and lack of tonicity-responsive gene expression.** *Proc Natl Acad Sci USA* 2004, **101**:2392-2397.
- Go WY, Liu X, Roti MA, Liu F, Ho SN: **NFAT5/TonEBP mutant mice define osmotic stress as a critical feature of the lymphoid microenvironment.** *Proc Natl Acad Sci USA* 2004, **101**:10673-10678.
- Jeon US, Kim JA, Sheen MR, Kwon HM: **How tonicity regulates genes: story of TonEBP transcriptional activator.** *Acta Physiol (Oxf)* 2006, **187**:241-247.
- Aramburu J, Drews-Elger K, Estrada-Gelonch A, Minguillon J, Moranco B, Santiago V, Lopez-Rodriguez C: **Regulation of the hypertonic stress response and other cellular functions by the Rel-like transcription factor NFAT5.** *Biochem Pharmacol* 2006, **72**:1597-1604.
- Trama J, Lu Q, Hawley RG, Ho SN: **The NFAT-related protein NFATLI (TonEBP/NFAT5) is induced upon T cell activation in a calcineurin-dependent manner.** *J Immunol* 2000, **165**:4884-4894.
- Woo SK, Kwon HM: **Adaptation of kidney medulla to hypertonicity: role of the transcription factor TonEBP.** *Int Rev Cytol* 2002, **215**:189-202.
- Loyher ML, Mutin M, Woo SK, Kwon HM, Tappaz ML: **Transcription factor tonicity-responsive enhancer-binding protein (TonEBP) which transactivates osmoprotective genes is expressed and upregulated following acute systemic hypertonicity in neurons in brain.** *Neuroscience* 2004, **124**:89-104.
- Maallem S, Mutin M, Kwon HM, Tappaz ML: **Differential cellular distribution of tonicity-induced expression of transcription factor TonEBP in the rat brain following prolonged systemic hypertonicity.** *Neuroscience* 2006, **137**:51-71.
- Wilkins BJ, Dai YS, Bueno OF, Parsons SA, Xu J, Plank DM, Jones F, Kimball TR, Molkentin JD: **Calcineurin/NFAT coupling participates in pathological, but not physiological, cardiac hypertrophy.** *Circ Res* 2004, **94**:110-118.
- Aramburu J, Yaffe MB, Lopez-Rodriguez C, Cantley LC, Hogan PG, Rao A: **Affinity-driven peptide selection of an NFAT inhibitor more selective than cyclosporin A.** *Science* 1999, **285**:2129-2133.
- Ko BC, Ruepp B, Bohren KM, Gabbay KH, Chung SS: **Identification and characterization of multiple osmotic response sequences in the human aldose reductase gene.** *J Biol Chem* 1997, **272**:16431-16437.
- Li SZ, McDill BW, Kovach PA, Ding L, Go WY, Ho SN, Chen F: **Calcineurin-NFATc signaling pathway regulates AQP2 expression in response to calcium signals and osmotic stress.** *Am J Physiol Cell Physiol* 2007, **292**:C1606-16.
- Chilton LA: **Prevention and management of hypernatremic dehydration in breast-fed infants.** *West J Med* 1995, **163**:74-76.
- Paut O, Andre N, Fabre P, Sobraques P, Drouet G, Arditti J, Camboulives J: **The management of extreme hypernatraemia secondary to salt poisoning in an infant.** *Paediatr Anaesth* 1999, **9**:171-174.
- Cooke CR, Wall BM, Jones GV, Presley DN, Share L: **Reversible vasopressin deficiency in severe hypernatremia.** *Am J Kidney Dis* 1993, **22**:44-52.
- Papadimitriou A, Kipourou K, Manta C, Tapaki G, Philippidis P: **Adipic hypernatremia syndrome in infancy.** *J Pediatr Endocrinol Metab* 1997, **10**:547-550.
- Ka T, Takahashi S, Tsutsumi Z, Moriwaki Y, Yamamoto T, Fukuchi M: **Hyperosmolar non-ketotic diabetic syndrome associated with rhabdomyolysis and acute renal failure: a case report and review of literature.** *Diabetes Nutr Metab* 2003, **16**:317-322.
- Schorn T, Manschwetus H, Kuhn KW: **Excessive hypernatremia in a patient with renal amyloid disease.** *Klin Wochenschr* 1991, **69**:436-439.
- Dogan E, Erkok R, Sayarlioglu H, Buyukbese A: **Nonketotic hyperosmolar coma in a patient with type I diabetes-related diabetic nephropathy: case report.** *Adv Ther* 2005, **22**:429-432.
- Yun J, Schoneberg T, Liu J, Schulz A, Ecelbarger CA, Promeneur D, Nielsen S, Sheng H, Grinberg A, Deng C, Wess J: **Generation and phenotype of mice harboring a nonsense mutation in the V2 vasopressin receptor gene.** *J Clin Invest* 2000, **106**:1361-1371.
- McDill BW, Li SZ, Kovach PA, Ding L, Chen F: **Congenital progressive hydronephrosis (cph) is caused by an S256L mutation in aquaporin-2 that affects its phosphorylation and apical membrane accumulation.** *Proc Natl Acad Sci USA* 2006, **103**:6952-6957.
- Ma T, Yang B, Gillespie A, Carlson EJ, Epstein CJ, Verkman AS: **Severely impaired urinary concentrating ability in transgenic mice lacking aquaporin-1 water channels.** *J Biol Chem* 1998, **273**:4296-4299.
- Trama J, Lu Q, Hawley RG, Ho SN: **The NFAT-related protein NFATLI (TonEBP/NFAT5) is induced upon T cell activation in a calcineurin-dependent manner.** *J Immunol* 2000, **165**:4884-4894.
- Esensten JH, Tsytsykova AV, Lopez-Rodriguez C, Ligeiro FA, Rao A, Goldfeld AE: **NFAT5 binds to the TNF promoter distinctly from NFATp, c, 3 and 4, and activates TNF transcription during hypertonic stress alone.** *Nucleic Acids Res* 2005, **33**:3845-3854.
- Ranjbar S, Tsytsykova AV, Lee SK, Rajsbaum R, Falvo JV, Lieberman J, Shankar P, Goldfeld AE: **NFAT5 regulates HIV-1 in primary monocytes via a highly conserved long terminal repeat site.** *PLoS Pathog* 2006, **2**:e130.

41. Lim SW, Ahn KO, Sheen MR, Jeon US, Kim J, Yang CW, Kwon HM: **Downregulation of renal sodium transporters and tonicity-responsive enhancer binding protein by long-term treatment with cyclosporin A.** *J Am Soc Nephrol* 2007, **18**:421-429.
42. Zhang Z, Ferraris JD, Irarrazabal CE, Dmitrieva NI, Park JH, Burg MB: **Ataxia telangiectasia-mutated, a DNA damage-inducible kinase, contributes to high NaCl-induced nuclear localization of transcription factor TonEBP/OREBP.** *Am J Physiol Renal Physiol* 2005, **289**:F506-F511.
43. Davies SP, Reddy H, Caivano M, Cohen P: **Specificity and mechanism of action of some commonly used protein kinase inhibitors.** *Biochem J* 2000, **351**:95-105.
44. Bain J, McLauchlan H, Elliott M, Cohen P: **The specificities of protein kinase inhibitors: an update.** *Biochem J* 2003, **371**:199-204.
45. Bain J, Plater L, Elliott M, Shpiro N, Hastie J, McLauchlan H, Klevvernic I, Arthur JS, Alessi DR, Cohen P: **The selectivity of protein kinase inhibitors; a further update.** *Biochem J* 2007, **408**:297-315.
46. Diehn M, Alizadeh AA, Rando OJ, Liu CL, Stankunas K, Botstein D, Crabtree GR, Brown PO: **Genomic expression programs and the integration of the CD28 costimulatory signal in T cell activation.** *Proc Natl Acad Sci USA* 2000, **99**:11796-11801.
47. Jones RG, Thompson CB: **Reving the engine: signal transduction fuels T cell activation.** *Immunity* 2007, **27**:173-178.
48. Celada A, Gray PVW, Rinderknecht E, Schreiber RD: **Evidence for a gamma-interferon receptor that regulates macrophage tumoricidal activity.** *J Exp Med* 1984, **160**:55-74.
49. Minguillon J, Morancho B, Kim SJ, Lopez-Botet M, Aramburu J: **Concentrations of cyclosporin A and FK506 that inhibit IL-2 induction in human T cells do not affect TGF-beta1 biosynthesis, whereas higher doses of cyclosporin A trigger apoptosis and release of preformed TGF-beta1.** *J Leukoc Biol* 2005, **77**:748-758.

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp

